(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 June 2012 (28.06.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/087746 A1

(51) International Patent Classification:
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2011/065174

(22) International Filing Date:
15 December 2011 (15.12.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/426,619 23 December 2010 (23.12.2010) US
61/540,882 29 September 2011 (29.09.2011) US

(71) Applicant *(for all designated States except US)*: **JANSSEN BIOTECH, INC.** [US/US]; 800/850 Ridgeview Drive, Horsham, PA 19044 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **STROHL, William** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **JORDAN, Robert** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **BREZSKI, Randall** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US).

(74) Agents: **DOW, Kenneth, J.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

[Continued on next page]

(54) Title: ACTIVE PROTEASE-RESISTANT ANTIBODY FC MUTANTS

(57) Abstract: Monoclonal antibody and other Fc-containing molecules can be constructed using the disclosed variations in the Fc region causing increased resistance to host and pathogen-derived proteases and exhibiting the ability to interact with Fey receptors and initiate complement directed cytotoxicity as demonstrated by functional assays. The Fc-containing molecules are useful in the treatment of various diseases and disorders wherein FcR-driven host functions contribute activity.

Fig. 1



S(219)-C-D-$K_1T_2H_3$T-C-P-P-C-P-A-$P_4E_5L_6$L-G_7G-P-S(239)

1 Plasmin
2 Human Neutrophil Elastase (HNE)
3 Papain
4 MMP-3, MMP-12
5 Glutamyl endopeptidase I (GluV8), Cathepsin G
6 Pepsin, MMP-7
7 IdeS

WO 2012/087746 A1

DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*